Precision BioSciences, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a DTIL research report →
Range $19 – $20
Price Chart
About the company
Precision BioSciences, Inc. is a clinical-stage biotechnology firm based in the United States, specializing in the creation of both in vivo gene editing solutions and ex vivo allogeneic CAR T-cell therapies. At its core is ARCUS, a proprietary genome editing platform designed to address and potentially cure genetic diseases.
- CEO
- Michael Amoroso
- IPO
- 2019
- Employees
- 67
- HQ
- Durham, NC, US
Get TickerSpark's AI analysis on DTIL
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $111.86M
- P/E
- -3.13
- PEG
- -0.02
- P/S
- 2.48
- P/B
- 4.98
- EV/EBITDA
- -1.08
- Div Yield
- 0.00%
- Gross Margin
- 100.00%
- Op Margin
- -80.78%
- Net Margin
- -117.04%
- ROE
- -91.60%
- ROIC
- -30.23%
Latest fiscal year · YoY change
- Revenue
- $34.26M-50.1%
- Gross Profit
- $34.26M-50.1%
- Op Income
- $-52,148,000
- Net Income
- $-45,724,000-738.0%
- EPS
- $-3.56-439.0%
- OCF Growth
- -12.7%
- FCF Growth
- -12.3%
- 52W High
- $9.62
- 52W Low
- $3.53
- 50D MA
- $7.50
- 200D MA
- $6.05
- Beta
- 1.23
- RSI (14)
- 71
- Avg Volume
- 434.33K
No earnings-call transcripts are available for DTIL yet.
- Free Float
- 76.7%
- Shares Outstanding
- 12.83M
- Float Shares
- 9.85M
of shares held by institutions
67 13F filers
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Vanguard Group Inc | 906.78K | ▲ 414.19K |
| Two Sigma Advisers, LP | 83.44K | ▲ 31.42K |
| Cwm, LLC | 1.00K | 0 |
Held by 71 ETFs
Biggest fund positions in DTIL by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Aug 1, 26 | Gorsuch Cassandra Louise | other | 0 |
| Aug 1, 26 | Gorsuch Cassandra Louise | other | 235 |
| Aug 1, 26 | Gorsuch Cassandra Louise | other | 585 |
| Aug 1, 26 | Gorsuch Cassandra Louise | other | 179,340 |
| Aug 1, 26 | Burris Mei Zhang Lu | other | 0 |
| Aug 1, 26 | Burris Mei Zhang Lu | other | 945 |
| Aug 1, 26 | Burris Mei Zhang Lu | other | 214 |
| Aug 1, 26 | Burris Mei Zhang Lu | other | 403 |
| Aug 1, 26 | Burris Mei Zhang Lu | other | 778 |
| Aug 1, 26 | Burris Mei Zhang Lu | other | 30,129 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our DTIL coverage
Recent articles, reports, and earnings notes.
Want a deeper read on DTIL?
Generate a full analyst-grade report — bull/bear case, price targets, valuation depth, and a complete financial breakdown.
Precision BioSciences: Promising HBV Editing Evidence
seekingalpha.com · Aug 18
Precision BioSciences Reports Second Quarter 2026 Financial Results and Provides Business Update
gurufocus.com · Aug 6
Precision BioSciences Reports Second Quarter 2026 Financial Results and Provides Business Update
businesswire.com · Aug 6
Precision BioSciences to Report Second Quarter 2026 Financial Results on August 6, 2026
businesswire.com · Jul 31
Precision BioSciences Announces Changes to Senior Leadership Team to Support Advancement of Programs Through Next Set of Clinical Milestones
businesswire.com · Jul 27
Precision BioSciences Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
businesswire.com · Jul 10
Strength Seen in Precision BioSciences (DTIL): Can Its 12.3% Jump Turn into More Strength?
zacks.com · Jul 8
Precision BioSciences Announces Inclusion in the Russell 2000® Index Expanding Market Visibility with Institutional Investors
gurufocus.com · Jun 29
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.